NULL

NULL

NULL

We identified that type 2 immunity stimulation has been associated with the pathogenesis of Systemic lupus Erythematous (SLE), so we studied serum level of IL 25 and its relation to SLE activity, clinical and laboratory characteristics. Methods: Serum from 90 patients who met the American College of Rheumatology (ACR) criteria for SLE and 40 healthy controls was tested for IL 25 level by Enzyme Linked Immunosorbent Assay (ELSIA). Clinical and laboratory characteristics and disease activity using SLE Disease Activity Index (SLEDAI) were also assessed. Results: IL 25 serum level was signi?cantly higher among SLE patients than healthy controls. It has statistically signi?cant correlation with disease activity. Conclusion: Our data indicates that IL 25 level is elevated in SLE patients in comparison to healthy controls and is correlated to high disease activity, potentially being a biomarker predictive for disease activity in SLE.

We identified that type 2 immunity stimulation has been associated with the pathogenesis of Systemic lupus Erythematous (SLE), so we studied serum level of IL 25 and its relation to SLE activity, clinical and laboratory characteristics. Methods: Serum from 90 patients who met the American College of Rheumatology (ACR) criteria for SLE and 40 healthy controls was tested for IL 25 level by Enzyme Linked Immunosorbent Assay (ELSIA). Clinical and laboratory characteristics and disease activity using SLE Disease Activity Index (SLEDAI) were also assessed. Results: IL 25 serum level was signi?cantly higher among SLE patients than healthy controls. It has statistically signi?cant correlation with disease activity. Conclusion: Our data indicates that IL 25 level is elevated in SLE patients in comparison to healthy controls and is correlated to high disease activity, potentially being a biomarker predictive for disease activity in SLE.

A correlation was detected between the chemokine CXC ligand 13(CXCL13) and lupus nephritis, but there is no data recorded in literature about a relationship with other disease manifestations in systemic lupus erythematosus (SLE). Therefore, we sought to investigate the relationship between CXCL13 and overall disease activity and other disease manifestations in SLE.

A correlation was detected between the chemokine CXC ligand 13(CXCL13) and lupus nephritis, but there is no data recorded in literature about a relationship with other disease manifestations in systemic lupus erythematosus (SLE). Therefore, we sought to investigate the relationship between CXCL13 and overall disease activity and other disease manifestations in SLE.

A correlation was detected between the chemokine CXC ligand 13(CXCL13) and lupus nephritis, but there is no data recorded in literature about a relationship with other disease manifestations in systemic lupus erythematosus (SLE). Therefore, we sought to investigate the relationship between CXCL13 and overall disease activity and other disease manifestations in SLE.

A correlation was detected between the chemokine CXC ligand 13(CXCL13) and lupus nephritis, but there is no data recorded in literature about a relationship with other disease manifestations in systemic lupus erythematosus (SLE). Therefore, we sought to investigate the relationship between CXCL13 and overall disease activity and other disease manifestations in SLE.

Interstitial lung disease (ILD) is the leading cause of systemic sclerosis (SSc) related morbidity and mortality,surpassing scleroderma renal crisis, which has become a rarity following the advent of angiotensin-converting-enzyme (ACE) inhibitors.High resolution computed tomography (HRCT) is the gold standard for diagnosis of in systemic sclerosis (SSc) related interstitial lung disease (SSc-ILD).